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Resumen:  La púrpura trombótica trombocitopénica (PTT) es un síndrome con alta mortalidad 
caracterizado por anemia hemolítica microangiopática, trombocitopenia y trombos microvasculares 
resultando en daño en múltiples sistemas.  Presentamos el caso de un hombre de 69 años quien presentó 
trombocitopenia, ictericia, dolor epigástrico, síntomas abdominales difusos y alteración del estado de la 
conciencia, 5 días después de recibir la vacuna de la influenza.  El cuadro clínico fue fulminante y llevó a su 
muerte antes del diagnóstico y tratamiento.  La autopsia mostró el diagnóstico de PTT.  La deficiencia de 
ADAMTS13 ha sido documentada ampliamente en la patogénesis de la PTT.  Auto-anticuerpos dirigidos hacia 
ADAMTS13 también han sido asociados en muchos casos, pero raramente la vacuna de la influenza se ha 
presentado como detonante de este padecimiento.   
 
Palabras clave: Púrpura trombótica trombocitopénica (PTT), factor von Willebrand, ADAMTS13, vacuna 
influenza. 
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Abstract:  Thrombotic thrombocytopenic purpura (TTP) is a life-threatening syndrome characterized by 
microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombi resulting in damage to 
multiple organ systems.  We present the case of a 69-year old male who presented with thrombocytopenia, 
jaundice, epigastric pain and altered mental status 5 days after receiving an influenza vaccination.  
Unfortunately, the clinical presentation was fulminant leading to death before the diagnosis of TTP and 
treatment with plasma exchange was done. Postmortem examination showed the diagnosis of 
TTP.  ADAMTS13 deficiency has been well documented as involved in the pathogenesis of TTP.  Auto-
antibodies against ADAMTS13 have also been implicated in many cases, but rarely with a trigger such as the 
influenza vaccination.   
 
Key words: Thrombotic thrombocytopenic purpura (TTP), von Willebrand factor (vWF), ADAMTS13, 
influenza vaccination 
 
 
 
INTRODUCTION  
 Thrombotic thrombocytopenic purpura 
(TTP) is a life-threatening syndrome characterized by 
microangiopathic hemolytic anemia, thrombocytopenia, 
and microvascular thrombi resulting in damage to 
multiple organ systems (1).  First described in 1924 by 
Dr. Eli Moschowitz (2), recent knowledge of its 
pathophysiology and importance of prompt diagnosis 
and management, has drastically diminished the high 
mortality rate associated with TTP from 80-90% to 10-
20% (3). 
A pentad of features has classically identified 
TTP: thrombocytopenia, microangiopathic hemolytic 
anemia (MAHA), renal failure, fever, and a varying 
degree of neurological abnormalities (4).  In view that 
all of these criteria are rarely present, unexplained 
hemolytic anemia and thrombocytopenia suffice to 
initiate treatment (1). 
We report a case of acquired TTP following 
influenza vaccination. 
 
 
CASE REPORT 
A 69 year old male presented with a 48 hour 
history of jaundice, epigastric pain, vomiting and 
altered mental status.  His medical history included a 
cerebrovascular accident at the age of 40 with the 
consequence of right hemiparesia and a preauricular 
basocelular carcinoma treated surgically and with 
radiation therapy in the year 2007. He did not take any 
medications. There had been no history of weight loss, 
recent viral illness, diarrhea, cough or previous 
episodes of jaundice. Five days prior to admission he 
was vaccinated against influenza with a commercial 
inactivated influenza vaccine (split virion) BP (Sanofi 
Pasteur MSD) as part of a routine vaccination program. 
On admission to the emergency room he was 
disoriented, pulse 115 beats per minute, blood pressure 
160/90 mmHg with an oxygen saturation of 89% on 
room air. He was jaundiced. His abdominal exam was 
normal and did not reveal hepatosplenomegaly. He did 
not have any hematomas or haemorrhages, rash or 
lymphadenopathy. The rest of the physical exam was 
unremarkable. 
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Laboratory exams and investigations performed are 
summarized in Table 1. 
Table 1. Laboratory analysis 
Haematology   
Haemoglobin 11.5 g/dl (12.5-16.5 
g/dl) 
White blood cell 
count 
7.0 x 103 (5-10 x 10 3) 
Platelets 9000/ mm3 (200000-
450000 
mm3) 
Bands 15%  
Metamyelocytes 3%  
Schistocytes None 
described 
 
Biochemistry   
Urea 58 mg/dl  (8-20 
mg/dl) 
Creatinine 1.8 mg/dl (0.6-1.3 
mg/dl) 
Direct Bilirubin 0.9 mg/dl (0.1-0.5 
mg/dl) 
Indirect 
bilirubin 
21.1 mg/dl (0.5-1 
mg/dl) 
Lactate 
dehydrogenase 
1875 IU/L (98-198 
IU/L) 
Alanine 
transaminase 
33 IU/L (17-63 
IU/L) 
Aspartate 
transaminase 
82 IU/L (15-41 IU/L) 
Protein 6.6 g/dl (6.4-8.3 
g/dl) 
Albumin 3.6 g/dl (3.5-5 g/dl) 
Prothrombin 
time 
11.1 sec (11-13.5 
sec) 
Partial 
thromboplastin 
time 
25.8 sec (20-30 sec) 
INR 1.03 1-1.1 
Table 1 continuation 
Urine Test   
Hematuria ++++  
Proteinuria +++  
Other Tests   
Computed 
tomography 
scan 
 ( brain) 
 
Old ischemic 
left 
periventricular 
lesion  
 
Abdominal 
Ultrasound 
Reported as 
normal 
 
Blood gases 
with 4L nasal 
cannula  
  
pH 7.4 (7.35-7.45) 
pC02 12.3 mmHg (30-41 
mmHg) 
p02 105.5 mmHg (83-108 
mmHg) 
HCO3 7.5  mmol/L (21-28 
mmol/L) 
 
 
 
There was progressive neurological worsening 
and 8 hours after admission to the emergency room the 
patient had a cardiac arrest and resuscitation 
maneuvers were unsuccessful. 
 The macroscopic autopsy findings were 
cardiomegaly (380g) with left ventricular concentric 
hypertrophy (1.9cm), congestive splenomegaly (320g), 
an old left hemispheric periventricular infarction along 
with petechial hemorrhages in the heart (Figure 1), 
liver, and kidneys. Microscopic examination revealed 
multiple microthrombi in arterioles and capillaries of 
myocardium (Figure 2), glomeruli (Figure 3), portal 
spaces, alveolar septae, skeletal muscle, and the brain. 
17 
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Fragmented erithrocytes (schistocytes) were found in 
glomeruli and myocardium with accompanying 
myocyte necrosis (Figure 4). The heart also showed 
coronary atherosclerosis and diffuse myocardial 
fibrosis (Figure 2) as an evidence for chronic ischemic 
cardiopathy with a reduced myocardial reserve that 
together with the newly formed microthrombi lead to 
death in this patient. This thrombotic microangiopathy 
is consistent with TTP given the clinical and laboratory 
findings. 
 
  
Figure 1.  Petechial hemorrhages in the endocardium. 
  
 
 
Figure 2.  Left: Myocardial microthrombus (black 
arrowhead) and erithrocyte extravasation (white 
arrowhead) (Hematoxilin-Eosin, 400x). Right: Intimal 
and myocardial fibrosis evidenced with aniline blue 
(Trichrome, 400x). 
 
 
Figure 3. Left: Microthrombus in the afferent arteriole of 
a glomerulus (white arrowhead) (Hematoxilin-Eosin, 
400x). Right: Fuchsinophilic microthrombi in the 
glomerular capillaries (black arrowheads) (Trichrome, 
400x). 
 
 
 
 
Figure 4. Left: Fragmented erithrocytes in a glomerulus 
(black arrowheads) (Hematoxilin-Eosin, 1000x). Right: 
Fragmented erithrocytes and myocardial necrosis 
(Trichrome, 1000x). 
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DISCUSSION 
Pathogenesis 
Thrombotic thrombocytopenic purpura (TTP) is 
a syndrome characterized by deposition of platelet 
thrombi in arterioles and capillaries (5).  There are two 
forms of TTP: Hereditary (Upshaw-Schulman 
syndrome) and acquired or idiopathic TTP.  Hereditary 
TTP is a result of a genetic mutation which leads to 
ADAMTS13 deficiency.  Acquired TTP is usually 
associated with auto-antibodies to ADAMTS13 (6, 7).  
Pathogenesis has, therefore, been attributed to a 
deficiency of a von Willebrand factor (vWF) protease 
termed ADAMTS13 (a disintegrin-like and 
metalloprotease with thrombospondin type 1 motif 13).  
The role that vWF and its protease play in the 
pathogenesis of TTP has been documented since the 
eighties but was not made clear until 1997 and 
subsequently identified through genetic linkage studies 
in 2001(5).  In congenital TTP the genetic locus is found 
on chromosome 9q34. 
Von Willebrand factor, a large glycoprotein 
synthesized in vascular endothelial cells, is an 
important mediator in platelet adhesion and 
aggregation.  Upon secretion into plasma, the unusually 
large von Willebrand factor (ULvWF) is cleaved by 
ADAMTS13, thereby preventing vWF from triggering 
additional blood clot formation.  Many mutations have 
been identified which can cause autoantibodies (IgG) 
against it. 
Additionally, numerous factors have been 
identified in patients without ADAMTS13 deficiency 
that have triggered acute TTP episodes.  These include, 
but are not limited to, autoimmune diseases, infections, 
drugs, pregnancy, bloody diarrhea, and hematopoeitic 
cell transplantation, with an idiopathic cause 
dominating the clinical setting (8).  Furthermore, TTP 
has also been clearly documented during acute stress in 
the postoperative period after cardiovascular surgery 
(9).  Another pathogenic mechanism attributed to TTP, 
besides ADAMTS13 deficiency, includes fibrinolysis 
impairment and the impairment of other proteases 
capable of cleaving vWF (such as plasmin, calpain, and 
cathespin) (5). 
Therefore, the deficiency of ADAMTS13, 
although a strong risk factor for developing TTP, is 
clearly not the only cause, and a trigger is frequently 
present in other idiopathic cases which ultimately leads 
to thrombotic microangiopathy (10). 
 
Clinical Presentation and Diagnosis 
As noted previously, an unexplained 
observation of hemolytic anemia and 
thrombocytopenia are the principal diagnostic findings 
that validate initiation of treatment (11).  Intravascular 
fragmentation of red blood cells, evidenced by 
schistocytes in the peripheral blood smear, is a result of 
intravascular platelet clumping (12).  High shear stress 
due to platelet aggregation also contributes to the 
variable signs and symptoms of organ ischemia and 
damage (5). 
Laboratory results show typical findings of 
hemolysis, including elevated serum lactate 
dehydrogenase (LDH) (13), an increase in indirect 
bilirrubin, a reduction in haptoglobin levels, and 
schistocytes.  This, in conjunction with 
thrombocytopenia, normal coagulation tests and the 
absence of another identifiable cause, should support 
the diagnosis and initiate urgent response and 
treatment. Other pathologies that might be considered 
in the differential diagnosis include: vasculitis and 
connective tissue diseases, hemolytic uremic syndrome, 
malignant hypertension, anti-phospholipid syndrome, 
systemic sclerosis, disseminated intravascular 
coagulation (DIC), malignancy, and Evans syndrome.   
It is important to note that the characteristic of 
TTP with the resultant endothelial injury is due to 
platelet-rich thrombi.  Therefore, the levels of the 
coagulation components, including prothrombin and 
partial thromboplastin times, are usually within normal 
limits.  This distinction is clearly relevant with another 
similar entity, as is diffuse intravascular coagulation 
(14). 
Urinalysis usually shows proteinuria and 
hematuria, but its degree can vary greatly among 
patients. 
19 
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Neurological abnormalities vary from mild 
symptoms such as headache and confusion to severe 
manifestations as in seizures, including coma (15). 
Fever is rarely encountered in patients with 
TTP. 
Vague abdominal symptoms may also be 
present, including epigastric pain, nausea, vomiting, and 
diarrhea. 
Cardiac involvement is associated with a higher 
morbidity and mortality rate in patients who developed 
TTP (16).  Complications such as arrhythmia, sudden 
cardiac death, myocardial infarction, cardiogenic shock, 
and heart failure are a direct consequence of platelet 
thrombi, ischemia, and necrosis in cardiac tissue. 
 
Treatment 
 Treatment is based on the underlying 
pathogenesis of TTP.  The standard treatment for TTP 
has been established as plasma exchange with fresh 
frozen plasma.  Plasmapheresis is variable within 
patients, but platelet count and serum lactate 
dehydrogenase (LDH) levels have been used as 
parameters to determine duration of treatment and 
remission.  A recent study suggested that LDH may not 
be such a reliable marker since its serum levels are also 
affected by other secondary processes (12).  LDH 
response was also determined to lag behind platelet 
recovery once treatment had begun. The additional use 
of corticosteroids (methylprednisolone 100mg IV every 
12hr) also improved survival rate; duration depended 
on the attending physician.  In cases of refractory or 
relapsing TTP, the addition of rituximab, azathioprine, 
or vincristine as an adjunct treatment has also been 
reported (12). 
 Rituximab is a chimeric monoclonal antibody 
directed against CD20.  Initially used in the treatment of 
non-Hodgkin lymphoma and chronic lymphocytic 
leukemia, additional uses have also successfully been 
documented in refractory cases of rheumatoid arthritis 
and autoimmune hematological diseases such as TTP.  
Its mechanism is not only attributed to B cell depletion 
but blockage of macrophage Fc-receptor function, 
thereby reducing platelet sequestration in the spleen 
(17).   Although rituximab therapy has been established 
as safe, caution should be taken due to some reports of 
life-threatening adverse effects, including hepatitis B 
reactivation and its related complications, progressive 
multifocal leukoencephalopathy (PML), neutropenia, 
intestinal perforation and obstruction, and delayed 
interstitial pneumonitis (18).    Most cases have been 
reported in immunosupressed patients with lymphoma 
(17).    HIV patients are also more susceptible to 
undesirable effects.  Recommendation of checking HIV 
and hepatitis B status in all patients before its 
utilization is a reasonable precaution.   Other 
anti-CD20 monoclonal antibodies have surfaced but are 
still in clinical trials, including ofatumumab, 
ocrelizumab, and veltuzumab.   
 As of now, the use of rituximab as adjunctive 
therapy seems to offer a therapeutic benefit to patients 
with relapsing TTP.    The majority of patients with TTP 
have received the same standard dose as patients with 
non-Hodgkin lymphoma, 375mg/m2 once a week for a 
total of four weeks.  Recent reports have shown positive 
outcomes with lower doses in immune mediated 
disorders(18).    Long term follow up of nine patients 
with idiopathic TTP refractory to plasma exchange 
treated with rituximab documented no side effects (19). 
 Another promising adjunct treatment that has 
also been suggested is that of recombinant ADAMTS13, 
but further investigation is still needed (20). 
 
CONCLUSIONS 
 Preventive medicine is an essential step in the 
reduction of morbidity and mortality.  Although 
recently a wide range of autoimmune diseases have 
surfaced as a consequence of immunization (21), rarely 
has vaccination been associated with TTP.  ADAMTS13 
deficiency due to either a hereditary or idiopathic cause 
has been clearly documented in the pathogenesis of 
TTP.  In this case the influenza vaccination seems to 
have served as a trigger for the acute TTP episode 
encountered. Interestingly, this patient also had a 
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previous thrombotic event at the age of 40.  
Unfortunately, testing for presence of auto-antibodies 
to ADAMTS13 or ADAMTS13 deficiency was not 
available in this case. Crucial in this life-threatening 
syndrome is prompt diagnosis and treatment.  
Therefore, microangiopathic hemolytic anemia 
associated with thrombocytopenia should strongly urge 
diagnosis of TTP with initiation of plasma exchange.   
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